WEKO3
アイテム
Evaluation of a PET-guided surgery with 64Cu-labeled cetuximab to resect tumors deeply located in the mouse peritoneal cavity
https://repo.qst.go.jp/records/72781
https://repo.qst.go.jp/records/727816c9c1829-7119-4301-b82c-7a40d5924f2c
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2018-05-10 | |||||
| タイトル | ||||||
| タイトル | Evaluation of a PET-guided surgery with 64Cu-labeled cetuximab to resect tumors deeply located in the mouse peritoneal cavity | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Yoshii, Yukie
× Yoshii, Yukie× Tashima, Hideaki× Iwao, Yuma× Takuwa, Hiroyuki× Yoshida, Eiji× Wakizaka, Hidekatsu× Yamaya, Taiga× Yoshimoto, Mitsuyoshi× Matsumoto, Hiroki× Zhang, Ming-Rong× Sugyo, Aya× Tsuji, Atsushi× Higashi, Tatsuya× 吉井 幸恵× 田島 英朗× 岩男 悠真× 田桑 弘之× 吉田 英治× 脇坂 秀克× 山谷 泰賀× 吉本 光喜× 松本 博樹× 張 明栄× 須尭 綾× 辻 厚至× 東 達也 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Background: Cytoreductive surgery is widely used for the treatment of peritoneal dissemination in clinical practice; however, it is difficult to detect and remove tumors that are located deeply in the peritoneal cavity and easily changing the position during an operation. We have found that a PET probe 64Cu-PCTA-anti-EGFR antibody cetuximab (64Cu-cetuximab) highly accumulates in intraperitoneal tumors by intraperitoneal administration. Also, we have developed the world's first open-type PET system, called "OpenPET", which has open space for conducting surgery while monitoring objects at high resolution in real time. In this study, we examined a feasibility of an OpenPET-guided surgery with 64Cu-cetuximab to detect and remove tumors deeply located in the peritoneal cavity. Methods: Mice bearing HCT116-RFP tumors transplanted with Matrigel at deep sites in the peritoneal cavity were used. 64Cu-cetuximab (7.4 MBq / mouse) was administered intraperitoneally and at 24 h later, the OpenPET-guided surgery was performed with a small prototype of OpenPET, having a spatial resolution of about 2 mm. All animal experiments were approved by the institutional ethics committee. Results: During OpenPET-guided surgery, tumors were clearly detected behind other organs in the peritoneal cavity. The measurement time required to accumulate sufficient data to identify tumors was approximately 10 – 30 s. Tumors (≥ 3 mm in diameter) located deep inside the peritoneal cavity could be resected by surgery with OpenPET real-time imaging. OpenPET was useful in confirming the presence or absence of residual tumors during an operation. Conclusions: We demonstrated that the OpenPET-guided surgery with 64Cu-cetuximab would be promising to detect and remove intraperitoneal tumors deeply located in the peritoneal cavity. This method could provide a novel strategy for cytoreductive surgery of peritoneal dissemination. | |||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 12th World congress of the world federation of nuclear medicine and biology | |||||
| 発表年月日 | ||||||
| 日付 | 2018-04-22 | |||||
| 日付タイプ | Issued | |||||
